- Home
- OPK vs ARQT Comparison
OPK vs ARQT Comparison
Compare OPK & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPK
- ARQT
- Stock Information
- Founded
- OPK 2007
- ARQT 2016
- Country
- OPK United States
- ARQT United States
- Employees
- OPK N/A
- ARQT 342
- Industry
- OPK Biotechnology: Pharmaceutical Preparations
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- OPK Health Care
- ARQT Health Care
- Exchange
- OPK Nasdaq
- ARQT Nasdaq
- Market Cap
- OPK 1.0B
- ARQT 2.1B
- IPO Year
- OPK 1995
- ARQT 2020
- Fundamental
- Price
- OPK $1.39
- ARQT $16.93
- Analyst Decision
- OPK Buy
- ARQT Strong Buy
- Analyst Count
- OPK 4
- ARQT 7
- Target Price
- OPK $2.75
- ARQT $19.00
- AVG Volume (30 Days)
- OPK 1.9M
- ARQT 1.6M
- Earning Date
- OPK 11-06-2025
- ARQT 11-05-2025
- Dividend Yield
- OPK N/A
- ARQT N/A
- EPS Growth
- OPK N/A
- ARQT N/A
- EPS
- OPK N/A
- ARQT N/A
- Revenue
- OPK $664,029,000.00
- ARQT $263,464,999.00
- Revenue This Year
- OPK N/A
- ARQT $72.46
- Revenue Next Year
- OPK $0.84
- ARQT $32.00
- P/E Ratio
- OPK N/A
- ARQT N/A
- Revenue Growth
- OPK N/A
- ARQT 99.50
- 52 Week Low
- OPK $1.11
- ARQT $8.03
- 52 Week High
- OPK $2.04
- ARQT $18.15
- Technical
- Relative Strength Index (RSI)
- OPK 51.08
- ARQT 57.20
- Support Level
- OPK $1.34
- ARQT $15.13
- Resistance Level
- OPK $1.44
- ARQT $18.15
- Average True Range (ATR)
- OPK 0.04
- ARQT 0.67
- MACD
- OPK -0.00
- ARQT 0.08
- Stochastic Oscillator
- OPK 45.00
- ARQT 60.00
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.